DEEP DIVE
📖 Prior auth reform is real (just not for derm).
UnitedHealthcare announced on May 5, 2026 that it is cutting prior auth on 30% of remaining services by year end, naming outpatient surgeries, echocardiograms, outpatient therapies, and chiropractic care. Not a single biologic, JAK inhibitor, or in-office injectable appears in the announcement.
What’s actually cut?
The 2025-2026 reform wave reads like progress on paper: UHC's 30% cut, Cigna's 25% cut from August 2023 removing 600+ codes, Humana's pledge to eliminate roughly a third of outpatient PAs, and the AHIP/BCBSA April 2026 update reporting 6.5 million fewer PAs across 250 million covered lives, an 11% reduction.
Read the small print and the exclusion language is identical across every announcement. Cigna's cut, Health Payer Intelligence noted, removed PA for "a wide range of tests, treatments and medical equipment, but not prescription drugs." Humana's announcement names diagnostic services and outpatient procedures and stops there. The AHIP commitments, per Paragon and McDermott+, "do not extend to prior authorization for prescription drugs."
That is exactly where dermatology lives. Paragon puts 41.2% of allowed commercial drug costs under prior auth, and 74% of Part B medication use (93% of Part B spending) subject to PA by at least one Medicare Advantage insurer. None of that pool is touched by any reform announced through May 2026.
What the carve-out costs
Carlisle and colleagues, JAMA Dermatology 2020, tracked one academic dermatology department over 30 days: 169.7 staff hours on prior auth, $5,822.98 in nonreimbursable staff time, $15.80 median cost per biologic PA, and biologic PAs at 11% of volume but 23% of staff time, with the longest biologic taking 31 business days. Jew and colleagues in JAAD ran the same kind of audit at a second academic center: 51% initial denial overall, 80% on systemic medications, 100% on biologics, with one patient waiting 70 days for lenalidomide. Two institutions, same pattern: biologics absorb disproportionate staff time and fail initial review at rates unrelated to clinical appropriateness, the same denial-on-arrival behavior practices see on repair claims. The fix-it step has its own gap: only 16% of physicians in the AMA's 2024 survey said the plan's "peer" reviewer often or always had the appropriate qualifications.
Why every reform track skipped drugs
Prior auth on specialty biologics runs through the pharmacy benefit, governed by PBMs, with separate utilization-management rules and separate political constituencies than the medical benefit. The 2025-2026 reforms all targeted the medical side, where carriers could put fast numbers on press releases without touching what generates the most denial revenue, the same dynamic behind the downcoding playbook on procedures.
Even the reform with the most teeth carved drugs out at the rule level. CMS's Interoperability and Prior Authorization Final Rule (CMS-0057-F) went live January 1, 2026 with 7-day standard and 72-hour expedited decision timelines plus a reason-for-denial requirement, covering Medicare Advantage, Medicaid, CHIP, and QHPs. Self-funded ERISA plans, where KFF's 2025 survey puts 67% of covered workers, are out of scope. On drugs, the CMS FAQ is explicit: "CMS excluded drugs from both the Prior Authorization application programming interface (API) and the process requirements for prior authorizations." CMS-0062-P, the proposed rule that would close the gap, was published April 14, 2026 with no effective date.
The state layer fills less than people expect. Texas HB 3459 was the first gold-card law in 2021, and five years in, state testimony summarized in MDedge put the qualifier rate at 3%, with AMA RUC chair Dr. Ezequiel Silva III calling the impact "underwhelming." The volume math is the reason: Texas requires 5+ PAs per service at 90% approval, and UnitedHealthcare's national program requires 10 per eligible code at 92%. A derm spreading a 200-patient biologics panel across Dupixent, Skyrizi, Tremfya, Cosentyx, Stelara, and Rinvoq fragments PA volume across J-codes and rarely hits any single threshold. Louisiana, Wyoming, and post-SB 833 West Virginia exclude drugs by statute. The CMS WISeR Model, launched January 1, 2026 in six states, runs the other direction: it adds PA to traditional Medicare, with vendors paid 10 to 20% of denial savings under what the AHA called a "perverse incentive to deny care."
Takeaways
Treat the March 31, 2026 transparency data as your benchmark. Pull the public PA reports for your top three Medicare Advantage payers and compare biologic approval rates and turnaround against your own log. The 19.48% standard denial rate and 74.52% appeal-overturn pattern from Kaiser Permanente Southern California's H0524 contract is the floor of defensibility.
Rebuild your biologic PA template around step-therapy documentation. Step therapy is in no reform. For psoriasis, name every failed prior therapy with dates, doses, and outcomes: methotrexate, cyclosporine, topical corticosteroids, phototherapy, prior biologic. For atopic dermatitis: topicals, calcineurin inhibitors, Eucrisa, and biologic before any JAK inhibitor. Bake this into the encounter template, not the appeal letter.
Monitor formulary updates monthly, not at renewal, and if you don't have your contracts on file, start there. Cigna's July 1, 2026 update revises quantity limits and PA on select medications. UnitedHealthcare pulled brand-name Stelara from its commercial PDL September 1, 2025 in favor of Steqeyma and Yesintek. Skyrizi was excluded from the 2024 Express Scripts National Preferred Formulary, routing most Cigna commercial plans through a Humira-Cosentyx-Tremfya step-fail.
Bottom line. The next signal to watch is the CMS-0062-P comment period. Whether the final rule extends to drugs, and whether commercial and self-funded plans ever come into scope, decides whether biologic prior auth looks different in 2027 or stays exactly the job it is today.
UPCOMING EVENTS + REMINDERS
📆 Mark your calendars:
Elevance 10% out-of-network penalty takes effect in California — June 1, 2026. Anthem/Elevance applies a 10% reimbursement reduction to non-contracted providers in California, with downstream effects on dermpath and hospital-Mohs referral patterns.
2. Massachusetts PA elimination on routine and essential care takes effect — June 5, 2026. Fully-insured commercial carriers in Massachusetts must drop PA on routine and essential care, with a 24-hour urgent decision window.
3. CMS-0062-P drug prior auth proposed rule — comment period closes — June 15, 2026. CMS proposes extending ePA standards to prescription drugs (72-hour standard / 24-hour expedited) for QHPs and Medicaid/CHIP — the rule that would close the drug carve-out described in this week's deep dive.
4. CAHPS for MIPS registration deadline — June 30, 2026. Practices that want to use CAHPS for MIPS as a 2026 reporting quality measure must register by this date or lose the option for the year.
5. HHS Most-Favored-Nation drug pricing — manufacturer compliance deadline — late July 2026. HHS issued MFN price targets in May 2026 to 17 manufacturers covering every major derm biologic; manufacturers face a roughly 60-day window before HHS moves to proposed rulemaking.
Until next week,
The Practice Layer, powered by Clarity RCM
Built by the people who do this every day.
Clarity RCM manages revenue cycle for 200+ dermatology practices across 42 states. It's all we do. See how we work.
